

Index

Note: page numbers in italics refer to figures and tables

- acetaminophen (paracetamol), 60, 136
- S-adenosylmethionine, 30
- adipocytokines, 39
- adipogenesis, neonate, 9
- adiponectin, 40, 172
- adipose tissue
 - adipocytokines, 39
 - risk of childhood asthma, 69
- adiposity, 9, 22
 - body mass index, 38, 191
 - childhood obesity, 138
 - complementary feeding, 22–23
 - folate concentrations in pregnancy, 29
 - maternal obesity, 40
- adolescence, 18
 - critical window, 18–19
 - metabolic disease, risk of, 13, 68
 - nutrition, 18
- Adverse Pregnancy Outcome (HAPO), 40
- ageing
 - biological, 129
 - chronological, 129
 - DNA damage, 126
 - epigenetic clocks, 129
 - glucocorticoid concentrations, 124–125
 - glucose-stimulated insulin secretion, 127
 - interactions in reproduction, 127–128
 - mechanisms, 128
 - metabolic programming, 126–127
 - protein-restricted and high-fat diets, 127
 - oxidative stress, 126
 - pancreatic islet secretory, 127
 - reactive oxygen species, 121
 - sex differences, 124
 - telomere shortening, 156
- age-related disease, 111, 154, 156
- air pollution, 56–58
 - death, 57
 - effects on
 - children, 57–58
 - pregnancy outcomes, 57
- airway
 - chronic inflammation, 100
 - fetal glucocorticoids, 124
 - growth
 - fetal and infant, 100
 - maternal smoking, 102
 - microbiome, 104
 - vitamin D, 181
- allergens
 - food, 58
 - vitamin D, 181
- Alzheimer’s disease, 59
- anaemia, 28
- anticipatory parental effects. *see* predictive adaptive responses (PARs)
- assisted reproductive technologies (ART), 2, 17, 75
 - impacts on offspring health, 75–77
- asthma
 - air pollution, 57–58
 - causality/confounding, 105–107
 - childhood, 60
 - early origins, 100
 - epigenetic mechanisms, 105
 - genetic origins, 101, 104
 - gestational age, 102
 - growth and body composition, 101–103
 - maternal
 - overweight and obesity, 100–101
 - smoking, 102
 - stress, 103
 - microbial factors
 - microbiome, 104
 - mode of delivery, 104
 - respiratory tract infections, 104
 - prediction tools, 107
 - symptoms, 100
 - unhealthy diet in early life, 103
- baby-led weaning, 23
- Barker Hypothesis, 1
- behavioral change interventions, 191
- biological methylation, 30
- biomarkers, epigenetic disease aetiology, 160
- birthweight
 - cardiovascular disease, 85, 189
 - complications of pregnancy, 22
 - diabetes
 - type 2, 85
 - hypertension, 93
 - kidney disease, 93
 - large offspring syndrome, 78
 - in low- and middle-income countries, 180
 - maternal blood TG concentrations, 40
 - maternal endurance exercise, 170
 - micronutrients, 29
 - nutritional supplementation, 33, 86
 - placental growth, 169
 - postnatal disease risk, 166
 - preimplantation embryo, 79
 - protein energy supplements, 30
 - undernutrition, 28
- blood pressure
 - in ART children, 77
 - arterial, 85
 - birthweight and undernutrition, 28
 - breastfeeding, 23
 - diabetic pregnancy, 93
 - food supplementation, 32
 - hormone stimulation, 76
 - maternal obesity, 38, 93
 - nephron number, 92
 - pregnancy, 91
 - preterm birth, 21
 - single micronutrients, 32
- body mass index (BMI)
 - childhood, early
 - asthma symptoms, 102
 - cow-milk fat consumption, 195
 - fat intake, 195
 - higher protein intake, 194
 - polyunsaturated fatty acids intake, 195
 - coffee and tea consumption, 197
 - complementary foods and beverages, 197
 - dairy consumption, 196
 - diabetes, 28
 - energy intake, 196

Index

- body mass index (cont.)
 - infant, 22
 - maternal, 38
 - sugar-sweetened beverages (SSBs)
 - effects, 195
 - dietary sugar intake, 196
 - fruit juice intake, 195–196
- brain
 - abnormalities, 140–141
 - anatomic changes, 139–141
 - cardiometabolic development
 - impacts, 218
 - chronic fetal hypoxia, 87–89
 - fatty acids, role, 183
 - growth rate, 18
 - hypothalamo-pituitary-adrenal axis, 46
 - maternal protein undernutrition, 18
 - maternal stress, 46, 52
 - maturation, 47
 - numbers of microglia, 50
 - offspring
 - mercury exposure, 59
 - structural and functional development, 52–53
 - structural and functional development, 51, 59
 - sympathetic-adrenomedullary system, 46
- brain-derived neurotrophic factor (BDNF) gene, 52
- breast cancer, 167
- breastfeeding, 23, 190
 - body mass index, 190
 - confounding factors, 191
 - duration, 190
 - overweight/obesity, 190
- caesarean births, attributable to
 - maternal obesity, 38
- calcium insufficiency, 181
- cancer
 - arsenic (As) exposure, 59
 - assisted reproductive technologies (ART), 75
 - breast, 168
 - childhood, risk of developing, 75
 - cryptorchidism and testicular, 59
 - early life environment, 111
 - epigenetic ageing, 156
 - epigenetic diseases, 159
 - gut microbiome, 66
 - high fat diet, 113
 - lung, 159
 - perinatal arsenic exposure risk, 59
 - preterm birth, 60
- cardiometabolic outcomes
 - animal models
 - glucocorticoid exposure, 89–90
 - hypoxia, developmental, 87–88
 - undernutrition, maternal, 86–87
 - human studies, 85–86
 - offspring
 - gestational diabetes, 91, 92
 - maternal obesity, 89–90
 - cardiomyocytes, 133
 - cardiovascular disease
 - developmental disease, 134–135
 - early life environment, 134
 - genetic variation, 156
 - global public health issue, 12
 - low birth weight, 85, 213
 - maternal obesity, 38
 - morbidity and mortality, 29
 - nephron number, 85
 - obesity, 11, 38, 90, 189
 - preterm birth, 21
 - undernutrition, 29
 - unhealthy ageing, 111
 - catechol-*O*-methyltransferase (COMT)
 - gene, 52
 - chemical pollution, 58
 - bisphenol, 59
 - metals and metalloids, 59
 - persistent organic pollutants, 58
 - pesticides, 60
 - pharmaceutical drugs, 60
 - phthalate esters, 59–60
 - children. *see also* fetus
 - cardiovascular health
 - maternal environmental influences, 75
 - conceived by *in vitro* fertilization (IVF)/frozen embryo transfer (FET), 75
 - cow-milk fat consumption, 195
 - DNA methylation effects, 30, 41
 - dysglycaemia and maternal overweight/obesity, 40
 - fat intake, 195
 - growth
 - protein energy supplements, 30–32
 - iron supplementation, 180
 - maternal antenatal dietary manipulation and, 42
 - metabolic syndrome, 40
 - obesity
 - epigenetic modifications, 41
 - maternal dietary manipulation to reduce, 41
 - polyunsaturated fatty acids intake, 192
 - protein intake, 194
 - risk of exposure to air pollution, 62
 - supplementation, impact of, 31
 - undernutrition, 27–28
 - climate change-induced, 60
 - vitamin D supplementation, 180
 - chromatin
 - epigenetic modifications, 147, 148
 - structure and gene activity, 151
 - chronic obstructive pulmonary disease (COPD), 100
 - climate change, 60–61
 - extreme heat, 61
 - infectious diseases, 61–62
 - natural disasters, 60
 - weather events, extreme, 61
 - complementary feeding
 - adiposity, 193, 194
 - timing, 193
 - types, 194
 - conceptus, 16
 - congenital anomalies
 - atrial septic defects, 57
 - coarctation of aorta and tetralogy of Fallot, 57
 - controlled ovarian (hyper) stimulation (COH), 77
 - conventional fluorescence microscopes, 141–142
 - corticotrophin releasing hormone (CRH), 49
 - C-reactive protein (CRP), 40
 - cytokines
 - pregnancy, 51
 - developmental mismatch
 - associated with, 11
 - conceptual framework of, 12
 - environment, 9
 - epigenetic clocks, 129
 - epigenetic modifications, 9
 - human niche modifying activities in, 11
 - immediate and predictive adaptive responses, 10
 - non-communicable diseases, risk of, 11
 - PARs, predictions of, 10
 - pregnancy and lactation, 20
 - developmental origins of health and disease (DOHaD), 1–5
 - anthropocene, 218
 - health policy, 216–218
 - life-course development, 217
 - mono-disciplinary, 218
 - state of science, 213–214
 - developmental plasticity, 9
 - fetus, growth of, 11
 - genetic mechanisms, 134
 - lactation, 20
 - mechanisms of, 10
 - multiple phenotypes, 9
 - pregnancy, 20–21
 - processes of, 10
 - structural modifications, 134

- developmental programming, 1
 - ageing, 123, 126–127
 - definition, 121
 - female ageing advantage, 123
 - glucocorticoid concentrations, 124–125
 - maternal
 - dietary intervention, 122
 - offspring voluntary moderate exercise, 123
 - overnutrition and obesity, 69
 - protein-restricted diet, 122
 - voluntary exercise, 123
 - principles of, 123–124
 - sex differences, 124
- diabetes type 1
 - pregnancy, 170
 - preterm birth, 21
- diabetes type 2, 8
 - birthweight, 135
 - developmental mismatch, 11
 - during pregnancy, 170
 - preterm birth, 21
 - risk factors, 9, 12, 8
- dichlorodiphenyldichloroethylene (DDE), 60
- dichlorodiphenyltrichloroethane (DDT), 60
- diethylstilbestrol, 60
- diet-induced obesity (DIO)
 - animal models, 113
- dioxins, 58
- disease
 - antibiotic exposure, 67
 - climate change
 - transmission and distribution of infections, 61–62
 - diarrhoeal, 62
 - DNA methylation effects, 30
 - early life, 27
 - environmental factors, 17
 - low birth weight, 85
 - preterm birth, 21–22
 - undernutrition, 28
- DNA methylation
 - gene expression regulation, 150
 - hydroxymethylcytosine, 147
 - imprinting, 153–154
 - X-chromosome inactivation, 151–152
- DNA replication-dependent, 150
- dysglycaemia, maternal, 39
 - child health outcomes, 41
 - manipulation of maternal diet, 41
 - overweight/obesity, 39–40
 - in pregnant women, 39–40
- dystocia, 11
- early life adversity (ELA), 111
 - cardiovascular disease risk, 134–135
- epigenetic reprogramming, 112–113
 - germ cells, 111–113, 112
 - growth and premature maturation, 113–114
 - menopause, earlier, 114
 - nutrient restriction, maternal, 114–116
- early-life exposures, perspective for wellbeing, 206–207
 - first 1000 days, 207–208
 - before first 1000 days, 208
 - preconception, 208–209
 - gestational weight, 208
 - lifestyle related behavior change, 208
 - obesity and associated metabolic conditions, 208
- education
 - formal, 208
 - overview, 203–204
 - potential, 208
 - process of transformation, 204
- embryo
 - culture
 - manipulating preimplantation, consequences, 78–79, 76
 - short- and long-term effects, 77–78
 - development in ART procedure, 77
 - environmental factors, 80
 - epigenetic modifications, 154
 - gametes, 154
 - paternal health, 79
 - pre-implantation period, 154
- environment
 - adult disease, 17
 - critical windows, 16
 - fertility, effects on, 17
- epidemiology, epigenetic, 160
- epigenetic clocks, 3, 156
- epigenetic disorders, 159
- epigenetic drift, 154
- epigenetics
 - cancers, 159
 - definition, 41, 146
 - environment interactions, 159–160
 - genomic imprinting, 153–154
 - hallmarks, 146–147
 - mechanisms
 - chromatin, 147, 148
 - DNA methylation, 147–150
 - gene expression, 150
 - higher order chromatin structure and gene activity, 151–152
 - histone variants and modification, 150
 - hydroxymethylation, 147–150
 - non-coding RNAs, 150, 148
 - modifications, 9
 - overview, 146
 - processes, 152
- X-chromosome inactivation, 152, 153
- epigenetic variation
 - disruption of sites, 156–157
 - DNA methylation, 156–157, 155
 - environmental exposures
 - animal models, 157
 - smoking and blood DNA methylation, 158
 - tissue-specific effects, 158
 - genetics and sex, 154
 - genetic variation in genes encoding, 157, 162
 - model for future human epigenetic studies, 158
 - phenotypic outcome, 162
 - sex specific effects, 157
- epigenome, 112
- evolutionary mismatch
 - adaptive traits/behaviours, 7
 - causes of, 9
 - history, 7
- evolutionary novelty, 10
- fat intake, early childhood, 195
- fetal brain sparing, 137
- fetal origins of adult disease (FOAD), 1
- fetal programming, 1
- fetus
 - bone development, 181
 - developmental plasticity, 10
 - environment
 - mismatch with neonate, 10
 - physiological conditions, 9
 - teratogenic effects, 9
 - growth of, 11
 - maternal constraint, 11
 - posttraumatic stress disorder, effects of maternal, 48
 - preterm birth, 21–22
 - transfer of stress from mother to cortisol, 50
 - cytokines and neuroactive metabolites, 51
 - epigenetic changes, 51
 - placental circulation, 51
 - vitamin D supplementation, 181
- folate concentrations, in pregnancy, 29
- food
 - insecurity, 27–28
 - security, 27
- fortified milk. *see* infant formula
- genomic imprinting, 153–154
- germ cells, 111–113
- gestational diabetes mellitus (GDM), 39, 85
 - evolutionary mismatch in, 7–8
 - interventions in women, 179–180
 - lifestyle interventions, 178, 185

Index

- gestational weight gain (GWG), 41
- glucocorticoids, 89–90
- glucose monitoring device (CGM), 179
- growth
 - fetal, 18
 - insulin-mediated, 39
 - post-lactation period, 22–23
 - post-natal, 22
 - posttraumatic stress disorder, 48
 - preterm birth, 21–22
 - stress-induced placental hypoperfusion and brain development, 52
- hormones effects, 52
- overweight and obesity, maternal, 100–101
- undernutrition, 28
- gut microbiome
 - immune system in early life, 69
 - colonization and inflammation, 69
 - NAFLD-programming, 69–70
 - initial colonization in newborns, 67
 - maternal, 66–67
 - obesity, development, 68–69
- health
 - personalised interventions, 177
 - respiratory diseases, 100
- hematopoietic stem cell (HSC), 70
- histone
 - code, 150
 - epigenetic modifications, 147
 - marks, 150
 - variants modifications, 150, 163
- histone acetyl transferases (HATs), 150
- histone code, 150
- histone marks, 150
- human health, niche modification, 12–13
- human milk oligosaccharides (HMOs), 67
- human rhino virus (HRV), 103
- Hyderabad Nutrition Program (HNP), 31
- hyperglycaemia, maternal, 40
- hyperglycemia, 179
- hyperinsulinaemia, obesity in pregnancy and, 40
- hyperinsulinemia, neonate, 9
- hypothalamic pituitary adrenal (HPA), 3
- hypothalamic pituitary adrenal (HPA) axis activity, in fetus, 51–52
- hypoxia, developmental, 87–89
- immediately adaptive responses (IARs), 10
- imprinting. *see* genomic imprinting
- infant formula, 191
- bacteria/non-digestible carbohydrates, addition, 192
- growth and body composition, 192
- long-chain polyunsaturated fatty acid, 192
- protein
 - composition, 191
 - contents, 191
 - soy-based, 191
- infant guideline score, 197
- infants
 - birth weight, 27
 - breastfeeding, 23
 - growth
 - adult health outcomes, 38
 - coronary heart disease, 33, 48
 - protein/energy maternal supplementation, 30–32
 - vitamin A supplementation, 30
 - kwashiorkor sufferers, 11–12
 - marasmic, 11–12
 - maternal blood TG concentrations and birthweight, 40
 - maternal BMI, effects of, 39
 - microbiome, maternal, 66–67, 70
 - spoon-feeding, 23
 - weight gain, 22
- insulin-like growth factor 2 IGF2/H19 locu, 52
- insulin resistance, 126
- interleukin-6 (IL-6), 40
- intrauterine growth restriction (IUGR), 139
- intra-uterine growth retardation (IUGR), 57
- intrauterine insemination (IUI), 76
- islets of Langerhans, 138, 139
- IVF and intracytoplasmic sperm injection (ICSI), 76
- kidney disease, 142
 - Barker and Brenner hypotheses, 92–93
 - developmental programming, 135, 169
 - low birth weight, 93
 - nephron number, 135
 - prenatal stress, 135–136
- kwashiorkor, 11–12
- lactation
 - developmental plasticity, 20–21
 - nutrition, 21–22
- lactocrine hypothesis, 20
- lead, maternal exposure effects, 59
- life-course model, 207
- lifestyle interventions, in pregnancy, 178, 179
- low birth weight (LBW), 57
- low-nutrition postnatal environment, 11
- malaria
 - anaemia, 61
 - cerebral, 61
- malnutrition
 - acute, 11
 - severe, 11
- mammalian target of rapamycin (mTOR), 138
- marasmus, 11–12
- maternal antenatal dietary manipulation, 41–42
- early childhood health, 42
- maternal constraint, 11
- maternal diet
 - nature of, 10
- maternal obesity. *see also* obesity
 - dietary manipulation, 41
 - metabolic impact, 39–40
 - risks and consequences, 38
- maternal protein restriction, 128
- maternal stress, in pregnancy, 50–53
 - anatomic changes to brain anatomy, 139–141
 - anxiety and depression, 47–48
 - childhood wheezing and asthma, risk of, 103
 - climate change, 61
 - effect of, before pregnancy, 48
 - mental health outcomes
 - offspring sex, 50
 - paternal stress and, 50
 - sociodemographic influences, 49–50
 - offspring cognitive and behavioral outcomes, 49
 - offspring mental health outcomes, 50–51
 - catecholamines, 52
 - growth hormones, 52
 - HPA axis activity and level of circulating cortisol, 51–52
 - neuroactive metabolites, 52
 - neuroinflammatory cytokines, 52
 - structural and functional brain development, 52–53
 - pathophysiological considerations, 49
 - post-delivery, 49
 - posttraumatic stress disorder, 48
 - psychosocial, 47, 49
- Mendelian randomisation (MR) methods, 3
- Mendelian randomization, 106–107, 162
- metastable epialleles (MEs), 30
- metformin, 42
- microbiome, 104
- micronutrient supplementation, in low- and middle-income countries, 180

- mixed interventions/exposures, 190
- mortality, 21
- myocardial ischemia, 134–135
- necrotizing enterocolitis, 66
- neonatal hypocalcaemia, 181
- neonate
 - environment mismatch with fetal, 10
 - hypoglycemia, 9
- neuropsychiatric disease, 140–141
- newborns
 - colonization, 67
 - necrotizing enterocolitis and sepsis, 67
- non-alcoholic fatty liver disease (NAFLD), 68
- pediatric, 69–70
- non-alcoholic steatohepatitis (NASH), 69
- non-communicable disease, 1
 - aetiology, 7
 - developmental mismatch, 11
 - as ‘lifestyle’ diseases, 12
 - preterm birth, 21–22
- noncommunicable diseases (NCDs), 214
- nutrition
 - early life, 27
 - metabolic disorders, 21
 - periconception, 17–18
 - undernutrition, 21
- obesity
 - Barker hypothesis, 189
 - childhood microbiome and, 68–69
 - developmental mismatch, 10–11
 - financial costs of, 38
 - lactation, 21
 - maternal, 17, 38
 - pregnancy, 20
 - lifestyle interventions, 178
 - risk of, 12, 13
- offspring
 - cardiometabolic outcomes
 - gestational diabetes, 91, 92
 - maternal obesity, 90–92
 - cardiovascular outcomes, 89
 - coffee and tea consumption, 197
 - DNA methylation effects, 30
 - monoamines, role of, 52
 - paternal health effects, 79
 - protein energy supplements, 30–32
 - renal outcomes of complicated pregnancy
 - animals models, 93–94, 94
 - human studies, 92–93
 - structural and functional brain development, 52–53
 - offspring sex, 50
 - omega 3 long-chain polyunsaturated fatty acids, 182
 - oocyte
 - oogenesis, 111
 - perturbation, 17
 - optical microscopy, 141
 - application, 142–143
 - multiplex imaging, 141–142
 - organochlorine pesticides (OCPs), 60
 - organophosphate pesticides (OPP), 60
 - over-nutrition hypothesis. *see* Pedersen hypothesis
 - oxidative phosphorylation, 126
 - paternal stress and mental health, 50
 - Pedersen hypothesis, 39
 - perfluoroalkyl substances (PFAS), 58–59
 - periconception
 - critical window, 19–20
 - environmental effects, 18
 - lifecourse stage, 20
 - maternal, 17–18
 - paternal, 17–18
 - posttraumatic stress disorder, 48
 - perinatology, 1
 - pesticide
 - organochlorine, 60
 - organophosphate, 60
 - pyrethroid, 60
 - phenotypic influences, 203
 - placenta, 166
 - amino acid transport, 169
 - barrier function, 166–167
 - birthweight
 - coronary heart disease, 169
 - risk of postnatal disease, 172
 - type 2 diabetes, 171
 - blood flow, 171
 - effects of SARS-CoV-2, 170
 - environmental exposures effects
 - epigenome, 171–172
 - gestational change, 171
 - hormone secretion, dysregulation, 171
 - evolutionary perspectives, 172
 - fetal growth, 171, 172
 - functional capacity, 169
 - gestational diabetes, 169
 - malperfusion, 170
 - maternal
 - body composition, 169
 - endurance exercise, 170
 - environment, 169
 - lifestyle factors, 170
 - nutritional status, 169
 - pregnancy-disorders, 170
 - methylation, 171–172
 - people and animal models, 167–169
 - periconceptual environment, 170–171
 - preeclampsia, 170
 - programming
 - in animal models, 172
 - epidemiological evidence, 172
 - signalling, maternal, 168
 - transport, mechanisms, 168
 - uterine, 170
 - placental dysfunction
 - developmental mismatch, 11
 - polybrominated diphenyl ethers (PBDEs), 59
 - polychlorinated biphenyls (PCBs), 58
 - polycystic ovary syndrome, 170
 - polyunsaturated fatty acids intake, early childhood, 195
 - post-lactation, 22–24
 - post-partum interventions, 184
 - posttraumatic stress disorder (PTSD)
 - preconception period and, 48
 - pregnancy/during childbirth, 48
 - preconception, 208–209
 - predictive adaptive responses (PARs), 10
 - accuracy, 11
 - characteristic of, 10
 - concept of, 10
 - in humans, 11–12
 - insulin resistance, 10
 - maternal diet, nature of, 10
 - pre-eclampsia, 38, 57, 170
 - pregnancy
 - calcium supplementation, 32
 - combination of protein energy and/or micronutrient supplements, 33
 - corticotrophin releasing hormone (CRH) synthesis, 49
 - definition, 21
 - developmental plasticity, 20
 - diabetes, 39
 - DNA methylation effects, 30, 41
 - folate concentrations, 29
 - folate maternal supplementation, 32–34
 - insulin and leptin concentrations, 39
 - iron
 - maternal supplementation, 32–34
 - manipulation of maternal diet, 41
 - maternal microbiota, 66–67
 - maternal obesity, effect of, 38
 - contribution of dysglycaemia, 39–40
 - maternal stress, 46–48
 - mental health and childhood outcomes, 182–183
 - metformin/insulin/placebo, 179
 - nutrition, 19–20
 - high fat diets, 21

Index

- pregnancy (cont.)
 - protein energy supplements, 30–32
 - pharmaceutical drugs, use of, 60
 - risk of exposure to air pollution, 57
 - supplementation, impact of, 30–31
 - undernutrition, 29
 - vitamin D supplementation, 181–182
- pregnancy-induced hypertensive disorders, 57
- premature delivery
 - neurological impairments, risk factor, 140
- prenatal stress
 - anatomical changes in kidneys, 135
 - liver fibrosis, 136–137
 - pancreatic adaptations, 137–138
- preterm birth
 - critical windows, 21–22
- primordial germ cells (PGCs), 111
- programme
 - village-based nutritional interventions, 31
- protein intake, early childhood, 194–195
- pyrethroid pesticides, 60
- randomised controlled trials (RCTs), 177
- respiratory syncytial virus (RSV), 104
- respiratory tract infections, 104
- rickets, 181
- science communication
 - challenges, 204
 - knowledge translation, 204–205
 - role of narrative, 206
 - overview, 147
 - transmission-based models, 204–205
- selective serotonin reuptake inhibitors (SSRIs), 60
- seminal plasma, 79
- sepsis, 67
- sexual dimorphism, in ageing, 127
- single nucleotide polymorphisms (SNPs), 104
- small for gestational age (SGA), 75
- smoking, 20
 - birthweight, 170
 - blood DNA methylation, 158
 - embryo culture, 77
 - fetal loss, 57
 - placenta, effects on, 169
 - pregnancy outcomes, 57
 - reduced birthweight, 170
 - wheezing and asthma risk, 102
- sodium valproate, 60
- stress. *see also* maternal stress, in pregnancy
 - anatomic changes to brain, 139–104
 - pancreatic adaptations, 137–138
 - prenatal
 - kidneys, anatomical changes, 135–136
 - liver fibrosis, 136–137
 - structured illumination (SIM), 141
- terminal differentiation, 134
- testicular antioxidant enzymes, 128
- Thalidomide, 60
- thalidomide tragedy, 1
- thin-fat phenotype, 29
- thrombo-embolic events, 38
- tobacco smoking, 56
- tumour necrosis factor alpha (TNF- α), 40
- undernutrition, maternal
 - animal models, 86–87
 - long-term diabetes risk, 28
 - micronutrient, 27–28
 - thin-fat phenotype, 29
- X-chromosome inactivation, 152